The Supreme Court gave the pharmaceutical industry a pair of victories on Thursday, shielding the makers of generic drugs from most lawsuits by injured patients and declaring that drug manufacturers had a free-speech right to buy private prescription records to boost their sales pitches to doctors.
In both decisions, the court's conservative bloc formed the majority, and most of its liberals dissented.
About 75 percent of the prescriptions written in the U.S. are for lower-cost generic versions of brand-name drugs. Federal law requires the original makers of the brand-name drugs to post an approved warning label and to update these warnings when reports of new problems arise.
No comments:
Post a Comment